Back to phosphodiesterase inhibitors for liver disease: Are we ready for clinical trials?

IF 12.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Pub Date : 2025-04-01 Epub Date: 2024-08-08 DOI:10.1097/HEP.0000000000001053

Leila Gobejishvili, Craig J McClain

引用次数: 0

查看原文本刊更多论文

回到治疗肝病的磷酸二酯酶抑制剂：我们准备好进行临床试验了吗？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology 医学-胃肠肝病学

CiteScore

27.50

自引率

3.70%

发文量

609

审稿时长

1 months

期刊介绍： HEPATOLOGY is recognized as the leading publication in the field of liver disease. It features original, peer-reviewed articles covering various aspects of liver structure, function, and disease. The journal's distinguished Editorial Board carefully selects the best articles each month, focusing on topics including immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases, liver cancer, and drug metabolism.